holdingMateria Medica- a Russian private manufacturing pharmaceutical company, founded in 1992, produces and sells more than 20 brands on the OTC market in Russia and the CIS, has its own research facilities.

Source: http: //www.materiamedica.ru

Materia Medica is one of the TOP-10 Russian and foreign pharmaceutical companies on the OTS market in Russia.

Research activities

Materia Medica is engaged in fundamental research in the field of ultra-low dose pharmacology

Materia Medica's Science and Clinical Research Departments cooperate with leading Russian and foreign research institutes and institutions in order to conduct joint research and obtain new experimental and clinical data. Among them:

• Center for Interferon and Cytokines of the State Institution of Research Institute of Epidemiology and Microbiology named after V.I. N.F. Gamalei RAMS (Moscow)
• Research Institute of Influenza SZO RAMS (St. Petersburg)
• Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow)
• First MGMU them. THEM. Sechenov (Moscow)
• Pirogov Russian National Research Medical University (Moscow)
• Institute for Antivirus Research (USA)
• L. Pasteur Institute (France).

Production

The Materia Medica plant has its own infrastructure to ensure production, is equipped with the latest high-tech equipment (L.B.Bohle, HÜTTLIN, Korsch, CAM).

Product quality is guaranteed by GMP certificates.

The suppliers of active pharmaceutical ingredients to Materia Medica are specialized, including immuno-biological, enterprises in Scotland, Switzerland and the Netherlands.

Manufacturing complex Materia Medica is located in Chelyabinsk. The company is one of the largest employers in this region.

Oleg Epshtein, the scientific director of Materia Medica Holding, explained the principle of action of release-active drugs

Oleg Epshtein, the scientific director of Materia Medica Holding, explained the principle of action of release-active drugs

Oleg Epstein, Doctor of Medical Sciences, Corresponding Member of the Russian Academy of Sciences, Scientific Director of NPF Materia Medica Holding LLC, answers the questions of the Rossiyskaya Gazeta correspondent.

Please tell us about your discovery, which is called release activity. How did you come to him?

After graduating from medical school, I worked as a psychiatrist for several years. I would like to note that I loved my work, I was especially interested in trends in psychopharmacology that were new for that time. Like most of my colleagues, I knew little about alternative medicine, including homeopathy, so I was negative about it. However, after perestroika, the opportunity presented itself to get acquainted with the basics of this unusual direction, to take the first official courses in homeopathy that appeared. I did not become a professional homeopath, but the method of treatment using small doses itself interested me from a scientific point of view.

Homeopathy, despite more than two hundred years of experience with this method, is too difficult to use - for a successful treatment, a homeopathic doctor must have a very high qualification. Classical homeopathy is an individual therapy and therefore cannot be part of modern evidence-based medicine. But most importantly, I began to realize that the principle of similarity, on which classical homeopathy is based, cannot explain all the effects that drugs in high dilutions cause.

For example, in the 70s and 80s of the last century, without any connection with homeopathy, famous scientists - chemists and biologists in many countries, including Russia (academician I.P. Ashmarin, professor E. B. Burlakova and many others), in the process of conducting biological experiments, noticed that various drugs, diluted to such an extent that theoretically do not contain molecules of the parent substance, are capable of exerting an effect in the body at the molecular level.

A fairly large array of experimental results on the biological effects of drugs in high dilutions (small doses) has been accumulated, but these studies did not lead to the creation of new drugs. First, I believe scientists have been held back by a critical attitude towards homeopathy. Secondly, there was no breakthrough, unambiguous understanding of the mechanism of the new phenomenon.

Gradually, I came to the conclusion that the clue lies in the very process of preparing high dilutions, which outwardly is a simple sequential repeated reduction in the concentration of the starting substance. I suggested that in fact, this is an extremely complex technological process, during which the emergence (release) of a set of new physicochemical and biological properties, called release activity, occurs in the resulting product.

The first step towards solving the mystery of high dilutions was taken in 1995, when we, together with well-known Russian research institutes, organized a series of experiments: animals were injected with toxic or subtoxic doses of conventional pharmacological drugs (prednisolone, diclofenac, phenazepam, haloperidol, cyclophosphamide, aspirin, etc.) etc.) and at the same time a high dilution (small dose) of the same drug. It turned out that in all cases the "small" dose had a modifying (to put it simply, catalytic) effect, which was manifested by an increase in the action of a pharmacological preparation and a decrease in its toxicity. Subsequently, we ourselves, and a number of scientists from fundamental physics institutes, established that high dilutions are capable of exerting a modifying effect on the original substance outside the body.

For the first time, the modifying properties of a technologically processed carrier discovered by us are an extremely useful practical finding that can be used both in medicine and in various fields of technology, including nanotechnology. Studying high dilutions, we cooperate with physicists, including theoreticians. The famous theoretical physicist S. Odintsov believes that the nature of high dilutions remains unexplored, but relevant, since the description of such liquids can lead to new fundamental discoveries.

For pharmacology, of course, first of all, the molecular mechanisms of action of small doses are important, which have now been studied in sufficient detail.

Are there other research groups developing the same ideas in Russia or abroad?

The studies carried out have shown that the new possibilities of the technology for obtaining high dilutions discovered by us open up the prospect of creating fundamentally new effective and safe drugs. I was well aware that new drugs should be developed by ourselves, since no one in Russia or abroad was involved in a similar topic. As a result, we on our own created a full-fledged research and production enterprise LLC "NPF" MATERIA MEDICA HOLDING "of the full cycle: from idea to finished dosage forms. Naturally, in order to organize such a production, I had to do a lot of self-education, immerse myself in different areas of knowledge : pharmacology, biology, immunology, pathophysiology. Over time, I defended my Ph.D. and doctoral dissertations under the guidance of my teachers - famous scientists, academicians - pharmacologist E. D. Goldberg and neurobiologist M. B. Stark; became a professor, and then was elected a member -correspondents of the Russian Academy of Sciences.

Like many other small firms, we work on a contract basis with specialized laboratories. At first, the necessary experimental work was carried out only in Russia, but gradually the geography expanded: at the moment we are cooperating with research organizations, universities and institutes of twenty countries, we publish the results obtained in Russian and Western journals. Our own clinical research department with a powerful statistical data processing unit independently conducts a large number of clinical trials, including international ones - in accordance with the requirements of the GCP; all of them are registered on a specialized electronic resource - www.clinicaltrials.gov.

The production of drugs at the plant in Chelyabinsk is carried out in full compliance with national and international requirements for good manufacturing practice (GMP).

As far as can be understood, the drugs that you are developing are not homeopathy?

Homeopathy is an individual therapy. From a modern point of view, the goal of homeopathic prescription is to try to induce the body's response to a drug in a small dose through the immunological mechanisms of individual sensitivity. Our scientific work allowed, in essence, to create a new class of biological drugs. In terms of preparation technology, it is similar to homeopathy, but according to modern principles of application based on the use of molecular approaches, as far as possible, a targeted effect on biological targets in the body, in terms of efficiency, and most importantly, as far as possible integration into evidence-based medicine is similar to "conventional" pharmacological drugs. Leading drug regulatory agencies in the US, England, Europe (FDA, MHRA, EMA) that we consulted also believe that our low dose antibody preparations are biological and not homeopathic.

At some point, the company acquired new drugs that were already invented within the company. Please tell us when and how it happened and what kind of drugs it was.

In cooperation with Academician M.B. Shtark, and then with specialists from other well-known Russian scientific institutes, we have developed a group of unparalleled drugs based on high dilutions of antibodies - proteins produced by the immune system. The main feature of these agents, which we call release-active antibodies, is their ability to specifically affect target molecules in the body, modifying their physicochemical properties, which leads to a positive change in the nature of the biological processes in which they are involved. This effect is physiological in nature and determines the therapeutic effect of release-active drugs.

Today, release-active drugs are used in various therapeutic areas.

The development of innovative biological preparations based on high dilutions of antibodies, which was attended by well-known Russian pharmacologists, physiologists, pharmacists and clinicians, was twice - in 2005 and 2006, awarded the RF Government Prize.

We really want to hope that our discovery will be further supported at the state level, and that the legal and regulatory issues inevitable in the implementation of any major undertaking will be resolved - for the sake of patients who need safe and highly effective medicines.

> Materia Medica Holding NPF, OOO (Moscow)

This information cannot be used for self-medication!
Consultation with a specialist is imperative!

The private pharmaceutical company Materia Medica Holding, founded in 1992, produces more than 20 traditional and innovative homeopathic medicines. The created preparations are the fruit of many years of research work by the company's team, as well as cooperation with national and foreign research institutions.

The production complex, located in Chelyabinsk, was designed and built in accordance with Good Manufacturing Practice (GMP) standards. It is equipped with modern equipment from the best suppliers and has two control laboratories - analytical and microbiological, equipped in accordance with the requirements of Good Laboratory Practice (GLP).

The products of Materia Medica Holding, already well known in Russia and the CIS countries, continue to gain popularity, entering the European and Asian markets.

Materia Medica Holding produces:

• non-hormonal homeopathic remedy Climaxan in granules and tablets, softening the manifestations of menopause in women;


• sedative drug Calm down in granules and tablets, eliminating irritability and nervousness;


• symptomatic homeopathic remedy Agri for adults and children, eliminating fever and inflammation with colds;


• homeopathic tablet Avia-Sea eliminating the symptoms of motion sickness in transport by increasing the resistance of the vestibular apparatus;


• Vernison- means in granules for the correction of falling asleep disorders;


• drug with cardiotonic and sedative action CardioIC in granules for the treatment of disorders in the work of the heart of a functional nature;


• Mlekoin in granules - a remedy for the correction of reduced production of breast milk in nursing;


• homeopathic pills Feminalgin eliminating or weakening the manifestations of premenstrual syndrome;


• remedy with analgesic and anti-inflammatory effects for sore throat Faringomed


• agents that stimulate the immune defense against respiratory viruses, Anaferon® and Anaferon® for children in tablets;


• homeopathic remedy with analgesic effect Arthrophone® in tablets, inhibiting the production of active mediators of inflammatory processes in the joints;


• anti-edema drug Afalu® in the form of tablets for the symptomatic treatment of prostate diseases;


• agent with a multifactorial mechanism of action Brizantin® in pills, eliminating withdrawal symptoms when smoking cessation;


• means of combating obesity Dietress® and Diet Comfort in pills, dulling hunger and reducing appetite;


• innovative nootropic agent Divazu® in tablets for the treatment of circulatory disorders of the brain;


• erectile function regulator Impazu® in tablets, increasing potency, regardless of the cause of its occurrence;


• a drug with anti-inflammatory and hypokinetic (slowing down motility) action Colofort® in tablets - the agent of choice in the treatment of irritable bowel syndrome;


• homeopathic remedies Proproten-100® in drops and tablets and Anti-e in drops for the treatment of alcohol addiction;


• sedatives Tenoten® and Tenoten® for children in tablets to relieve anxiety, irritability, nervousness;


• agent with antiviral and antihistamine properties Ergoferon® in tablets for the accelerated treatment of respiratory viral infections;


• lozenges Nikomel® that weaken the dependence on nicotine;


• homeopathic remedy For poets® in tablets, stimulating the formation of red blood cells in case of anemia;


• antiallergic agent Progist® in lozenges;


• homeopathic antihypertensive drug Cardosten® in lozenges, effective in the treatment of arterial hypertension;


• antiulcer Epigam® tablets suppressing the production of hydrochloric acid in the stomach and helping to accelerate the healing process;


• excipient sugar grits for the production of homeopathic remedies in the form of granules.

Open data from the Internet: LLC NPF "Materia-Medica Holding", authorized capital of 100 thousand rubles (1500 dollars, a "huge" amount for a pharmaceutical company).

Guys have been pumping money out of thin air for over 20 years. Well done, what else to say, I sincerely envy.

However, you do not have to pay them at all.

The author of the site is a strict adherent of evidence-based medicine (all sorts of levels of evidence I, II, III, IV, find on the Internet, who are interested) and when studying drugs, he persists in looking for these numbers in information about drugs, so as not to recommend outright bullshit to readers.

So let's get to know the company by examining the official website (quotes copied on November 23, 2016).

History page:

"Founded in 1992, Materia Medica Holding launched the first mass production in Russia HOMEOPATHIC drugs and made them available to a wide range of consumers. "

"By the end of the 90s, the company's portfolio already included 10 HOMEOPATHIC drugs from different (Oh how!) pharmacological groups. Thanks to its high safety profile combined with efficiency, HOMEOPATHIC the drugs quickly won the trust of doctors and patients. "

I quote so that it is clear where the legs grow from and why the production was created. Keyword HOMEOPATHY(that is, dilutions of supposedly active substances in billions of times, so that not a single molecule of "medicine" remains in the pill).

Company page:

"Research in accordance with GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) requirements guarantee a high profile SAFETY drugs. In 2015-2016, Materia Medica conducted preclinical studies at 29 bases and clinical studies at 182 bases. "

About SECURITY written, but about EFFICIENCY not a word, and nothing about any studies with classes of proof. That is, according to the official website of the company, it is clear that the homeopathic office EFFICIENCY their drugs are not fundamentally puzzled. Draw conclusions.

And the safety, for example, of tap water is also good, only the price is cheaper.

Materia Medica preparations on the international pharmaceutical site Vidal

We go http://www.vidal.ru/drugs/firm/961. We would like to draw your attention to the fact that the preparations before 2010 are labeled as "homeopathic", and after 2010 the word "homeopathy" disappears from the descriptions.

Apparently, then the company’s marketers realized that homeopathy couldn’t go too far, and began rubbing the illiterate population that they were producing incredibly effective AFFINALLY PURIFIED ANTIBODIES to any regulatory substances. In the new rewritten instructions, there are many obscure words, fiction "inspires", advertising on TV broadcasts, sales are going on.

But. ANTIBODIES ARE PROTEINS, all of the company's "antibodies" come in pills and are taken by mouth. But that's bad luck, that's all PROTEINS in the gastrointestinal tract SPLIT TO COMMON Dietary Amino Acids and there can be no question of any therapeutic effect of the protein (http://meduniver.com/Medical/Physiology/1154.html).

Besides, NO ONE the company's drug is not positioned in the ATX international drug classification, NO ONE the drug does not have an international non-proprietary name (INN). That is, this is such a small-town Russian office for buyers with large ears, on which it is convenient to hang noodles.

By the way, since 2016, the US Food and Drug Administration (FDA) has obliged homeopathy manufacturers to indicate the truth on the label (https://hightech.fm/2016/11/18/gomeopatia). I think this will not happen soon in our country.